Recent clinical trials have demonstrated promising efficacy of antibody-drug conjugates (ADCs) targeting DLL3 in aggressive small cell lung cancer (SCLC). Merck and Daiichi Sankyo's ADC showed substantial tumor shrinkage in nearly half of patients in a mid-stage trial, while SHR-4849, a novel DLL3-targeted ADC, delivered encouraging results in a first-in-human trial for relapsed SCLC. Additionally, the IDeate-Lung01 Phase 2 trial reported high response rates for ifinatamab deruxtecan in previously treated extensive-stage SCLC. These advancements highlight potential new therapeutic options for a cancer subtype with historically limited treatments.